ArticlePloS one2013
Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Methylation and copy number profiling: emerging tools to differentiate osteoblastoma from malignant mimics?Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.Virchows Archiv : an international journal of pathology · 2021Article
- Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.Rare tumors · 2021Article
- Loss of NF2 defines a genetic subgroup of non-FOS-rearranged osteoblastoma.The journal of pathology. Clinical research · 2020Article
- [Molecular pathology in the diagnosis of bone tumors: current concepts].Der Pathologe · 2020Review
- [Osteoid-forming bone tumors : Morphology and current translational cell biology].Der Pathologe · 2020Review
- What's new in bone forming tumours of the skeleton?Virchows Archiv : an international journal of pathology · 2020Review
- Osteoblastoma of the clavicle at the site of a previous fracture-first case report and review of the literature.Skeletal radiology · 2019Review
- A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis.Genes & development · 2019Article
- Genomic Analysis Does Not Support Malignant Transformation of Osteoblastoma to Osteosarcoma.JCO precision oncology · 2019Article
- Recurrent rearrangements of FOS and FOSB define osteoblastoma.Nature communications · 2018Article
- Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2017Article
- Article
- ZNRF3 contributes to the growth of lung carcinoma via inhibiting Wnt/β-catenin pathway and is regulated by miR-93.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.The Journal of clinical endocrinology and metabolism · 2015Article
- Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors.Frontiers in endocrinology · 2015Review
- Metachronous osteoblastoma of the spine and osteoid osteoma of the femur.BJR case reports · 2015Article
- Bone- and cartilage-forming tumors and ewing sarcoma: an update with a gnathic emphasis.Head and neck pathology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoblastoma is a bone forming tumor with histological features highly similar to osteoid osteoma; the discrimination between the tumor types is based on size and growth pattern. The vast majority of osteoblastomas are benign but there is a group of so-called aggressive osteoblastomas that can be diagnostically challenging at the histopathological level. The genetic aberrations required for osteoblastoma development are not known and no genetic difference between conventional and aggressive osteoblastoma has been reported. In order to identify recurrent genomic aberrations of importance for tumor development we applied cytogenetic and/or SNP array analyses on nine conventional and two aggressive osteoblastomas. The conventional osteoblastomas showed few or no acquired genetic aberrations while the aggressive tumors displayed heavily rearranged genomes. In one of the aggressive osteoblastomas, three neighboring regions in chromosome band 22q12 were homozygously deleted. Hemizygous deletions of these regions were found in two additional cases, one aggressive and one conventional. In total, 10 genes were recurrently and homozygously lost in osteoblastoma. Four of them are functionally involved in regulating osteogenesis and/or tumorigenesis. MN1 and NF2 have previously been implicated in the development of leukemia and solid tumors, and ZNRF3 and KREMEN1 are inhibitors of the Wnt/beta-catenin signaling pathway. In line with deletions of the latter two genes, high beta-catenin protein expression has previously been reported in osteoblastoma and aberrations affecting the Wnt/beta-catenin pathway have been found in other bone lesions, including osteoma and osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.